A 25-Year Prospective Study of Plasma Adiponectin and Leptin Concentrations and Prostate Cancer Risk and Survival
Open Access
- 1 January 2010
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 56 (1), 34-43
- https://doi.org/10.1373/clinchem.2009.133272
Abstract
Background: Adipocytokines may mediate the association between adiposity and lethal prostate cancer outcomes. Methods: In the Physicians’ Health Study, we prospectively examined the association of prediagnostic plasma concentrations of adiponectin and leptin with risk of developing incident prostate cancer (654 cases diagnosed 1982–2000 and 644 age-matched controls) and, among cases, risk of dying from prostate cancer by 2007. Results: Adiponectin concentrations were not associated with risk of overall prostate cancer. However, men with higher adiponectin concentrations had lower risk of developing high-grade or lethal cancer (metastatic or fatal disease). The relative risk (95% CI) comparing the highest quintile to the lowest (Q5 vs Q1) was 0.25 (95% CI 0.07–0.87; Ptrend = 0.02) for lethal cancer. Among all the cases, higher adiponectin concentrations predicted lower prostate cancer–specific mortality [hazard ratio (HR)Q5 vs Q1= 0.39; 95% CI 0.17–0.85; Ptrend = 0.02], independent of body mass index (BMI), plasma C-peptide (a marker of insulin secretion), leptin, clinical stage, and tumor grade. This inverse association was apparent mainly among men with a BMI ≥25 kg/m2 (HRQ5 vs Q1= 0.10; 95% CI 0.01–0.78; Ptrend = 0.02), but not among men of normal weight (Ptrend = 0.51). Although the correlation of leptin concentrations with BMI (r = 0.58, P < 0.001) was stronger than that of adiponectin (r = −0.17, P < 0.001), leptin was unrelated to prostate cancer risk or mortality. Conclusions: Higher prediagnostic adiponectin (but not leptin) concentrations predispose men to a lower risk of developing high-grade prostate cancer and a lower risk of subsequently dying from the cancer, suggesting a mechanistic link between obesity and poor prostate cancer outcome.Keywords
Funding Information
- Prostate Cancer Foundation
- NIH (CA42182, CA58684, CA90598, CA34944, CA40360)
- Department of Defense
- Merck
This publication has 41 references indexed in Scilit:
- Metformin use and prostate cancer in Caucasian men: results from a population-based case–control studyCancer Causes & Control, 2009
- New Users of Metformin Are at Low Risk of Incident CancerDiabetes Care, 2009
- Cancer metabolism and the dynamics of metastasisJournal of Theoretical Biology, 2009
- Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysisThe Lancet Oncology, 2008
- Dietary supplementation with ω-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overloadCardiovascular Research, 2007
- The regulation of adiponectin receptors in human prostate cancer cell linesBiochemical and Biophysical Research Communications, 2006
- Adiponectin as a growth inhibitor in prostate cancer cellsBiochemical and Biophysical Research Communications, 2006
- Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3Biochemical and Biophysical Research Communications, 2005
- AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanismsBiochemical and Biophysical Research Communications, 2004
- Adiponectin differentially regulates cytokines in porcine macrophagesBiochemical and Biophysical Research Communications, 2004